Andreas Hartmann, PhD
Executive Director, Preclinical Safety
Therapeutic Area Head Neuroscience
PhD in Genetic Toxicology (University of Ulm, Department of Human Genetics; Germany); Research Fellow at University of California, San Francisco (UCSF) in Radiation Oncology.
Global Therapeutic Area Head Neuroscience at Novartis Pharma, Switzerland. Overseeing a global team of senior project toxicologists characterizing the non-clinical safety profile of small molecules, monoclonal antibodies, anti-sense oligonucleotides and rAAV-vector based gene therapy drug candidates from target identification to post-marketing. 24+ years of experience in non-clinical safety profiling in pharmaceutical industry.
Select External Activities:
Past Chair of the EFPIA Preclinical Development Expert Group (PDEG) (2018-2021)
Editorial Board Member – Mutation Research, Genetic Toxicology and Environmental Mutagenesis
Member of IMI SafeSciMET (European Training and Education initiative) Executive Committee
55+ peer-reviewed publications, mainly in the field of genetic toxicology